2.44
+0(+0.00%)
Currency In USD
| Previous Close | 2.44 |
| Open | 2.38 |
| Day High | 2.44 |
| Day Low | 2.38 |
| 52-Week High | 414.7 |
| 52-Week Low | 2.23 |
| Volume | 130,729 |
| Average Volume | 3.1M |
| Market Cap | 5.82M |
| PE | 0.01 |
| EPS | 264.12 |
| Moving Average 50 Days | 5.85 |
| Moving Average 200 Days | 76.86 |
| Change | 0 |
If you invested $1000 in ReShape Lifesciences Inc. (RSLS) since IPO date, it would be worth $0 as of June 30, 2025 at a share price of $2.44. Whereas If you bought $1000 worth of ReShape Lifesciences Inc. (RSLS) shares 5 years ago, it would be worth $0.02 as of June 30, 2025 at a share price of $2.44.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
GlobeNewswire Inc.
Jun 27, 2025 1:01 PM GMT
IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasd
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
GlobeNewswire Inc.
Jun 26, 2025 12:31 PM GMT
Reduction in Force Estimated to Save Over $750K or 23.4% of Annual Payroll Expenses Agreements Progress Toward Completion; Shareholder Meeting Scheduled for July 24, 2025 IRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
GlobeNewswire Inc.
Jun 25, 2025 12:31 PM GMT
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and HypoglycemiaIRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions c